Management and outcome of stage 3 neuroblastoma

European Journal of Cancer

Volumn 45, Issue 1, 2009, Pages 90-98

  Modak, Shakeel ^a   Kushner, Brian H ^a   LaQuaglia, Michael P ^a   Kramer, Kim ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunotherapy; Prognosis; Stage 3 neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 57649183853     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.09.016     Document Type: Article

References (33)

1. Brodeur G., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11 (1993) 1466-1477
2. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 933-70.
3. Bagatell R., Rumcheva P., London W.B., et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumour cell ploidy. J Clin Oncol 23 (2005) 8819-8827
4. Rubie H., Hartmann O., Michon J., et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of a french NBL study. J Clin Oncol 15 (1997) 1171-1182
5. George R.E., Li S., Medeiros-Nancarrow C., et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 24 (2006) 2891-2896
6. Berthold F., Boos J., Burdach S., et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6 (2005) 649-658
7. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. New Engl J Med 341 (1999) 1165-1173
8. Matthay K.K., Perez C., Seeger R.C., et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a children's cancer group study. J Clin Oncol 16 (1998) 1256-1264
9. Cheung N.K.V., Kushner B.H., LaQuaglia M.P., et al. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biologic markers. Eur J Cancer 33 (1997) 2117-2121
10. Kushner B.H., Cheung N.K., LaQuaglia M.P., et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 14 (1996) 373-381
11. Cecchetto G., Mosseri V., De Bernardi B., et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group. J Clin Oncol 23 (2005) 8483-8489
12. Simon T., Hero B., Benz-Bohm G., von Schweinitz D., and Berthold F. Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial. Pediatr Blood Cancer 50 (2008) 965-969
13. Cheung N.K., Kushner B.H., LaQuaglia M., et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 36 (2001) 227-230
14. Kushner B.H., Kramer K., and Cheung N.K.V. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19 (2001) 4189-4194
15. 15 Kreissman S.G., Villablanca J.G., Diller L., et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction for high-risk neuroblastoma: a Children's Oncology Group (COG A3973) study. J Clin Oncol 25 (2007) 9505
16. Garaventa A., Boni L., Lo Piccolo M.S., et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 13 (2002) 956-964
17. Laverdiere C., Cheung N.K., Kushner B.H., et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 45 (2005) 324-332
18. De Bernardi B., Conte M., Mancini A., et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 13 (1995) 884-893
19. 19 Kushner B.H., LaQuaglia M.P., Ambros P.F., et al. Survival from locally invasive or metastatic neuroblastoma (NB) without cytotoxic therapy (Rx). Proc Am Soc Clin Oncol 12 (1993) 413
20. Park J.E., London W., Maris J.M., et al. Prognostic markers for stage 3 neuroblastoma (NB): a report from the International Neuroblastoma Risk Group (INRG) project. Proc ASCO (2008)
21. Baker D.L., Schmidt M., Cohn S.L., et al. A phase III trial of biologically-based therapy reduction for intermediate risk neuroblastoma. Proc ASCO 25 S (2007) 9504
22. Strother D., van Hoff J., Rao P.V., et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Paediatric Oncology Group. Eur J Cancer 33 (1997) 2121-2125
23. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. New Engl J Med 353 (2005) 2243-2253
24. Maris J.M., Weiss M.J., Guo C., et al. Loss of heterozygosity at chromosome 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a children's cancer study group study. J Clin Oncol 18 (2000) 1888-1899
25. Cheung N.K., Kushner B.H., LaQuaglia M., et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 36 (2001) 227-230
26. Wolden S.L., Gollamudi S.V., Kushner B.H., et al. Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys 46 (2000) 969-974
27. Cheung N.K., Sowers R., Vickers A.J., Cheung I.Y., Kushner B.H., and Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 24 (2006) 2885-2890
28. Laprie A., Michon J., Hartmann O., et al. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system stage II and III neuroblastoma with MYCN amplification. Cancer 101 (2004) 1081-1089
29. Simon T., Spitz R., Faldum A., Hero B., and Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 26 (2004) 791-796
30. Hero B., Simon T., Spitz R., et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 26 (2008) 1504-1510
31. Cheung N.K., Lazarus H., Miraldi F.D., et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5 (1987) 1430-1440
32. Matthay K.K., Seeger R.C., Reynolds C.P., et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. J Clin Oncol 12 (1994) 2382-2389
33. Kushner B.H., Cheung N.K., Kramer K., Dunkel I.J., Calleja E., and Boulad F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumours, and other poor-risk solid tumours in children and young adults. Bone Marrow Transplant 28 (2001) 551-556